Bladder Cancer
Conditions
Keywords
Bladder Cancer, Non-muscle invasive bladder cancer, MCM5, Biomarker, Urinary biomarker, Follow-up, Surveillance
Brief summary
The objective of this prospective, multi-centre study is to evaluate the performance of ADXBLADDER, a urine MCM5 ELISA test, as an aid in the detection of bladder cancer recurrence. Patients undergoing cystoscopic surveillance in non-muscle invasive bladder cancer (NMIBC) follow-up will be recruited and asked to provide a urine sample to be tested with ADXBLADDER. To assess the diagnostic accuracy of the test, the MCM5 results will be compared with the gold standard cystoscopy and pathology of resected tissue.
Interventions
DIAGNOSTIC_TESTADXBLADDER
ADXBLADDER is a non-invasive, qualitative ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the monitoring of bladder cancer recurrence in non-muscle-invasive bladder cancer patients. Participants will be asked to provide a full void urine specimen, which will be centrifuged before the urine sediment is lysed. The lysed sample will then be tested with ADXBLADDER.
Sponsors
Arquer Diagnostics Ltd
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who have been diagnosed with NMIBC in the previous 2 years, and are attending the urology clinic for standard of care/routine monitoring cystoscopy * Patients 22 years of age or older * Patients who, in the opinion of the Investigator, are suitable for standard urological investigations as part of normal clinical practice * Patients who are, in the opinion of the Investigator, able to understand the purpose of the study and provide a full void urine specimen * Patients who are able to give voluntary, written informed consent to participate in this study
Exclusion criteria
* Patients with known active (symptomatic) calculi within the urino-genitary system * Patients who provide less than 10mL of full void urine * Patients undergoing active treatment for interstitial cystitis * Patients currently undergoing systemic chemotherapy or systemic immunotherapy or radiotherapy. Intravesical chemotherapy or immunotherapy (BCG) is allowed * Patients who have previously been diagnosed with renal cancer, prostate cancer, Muscle Invasive Bladder cancer, an upper tract tumour, or CiS in the prostatic urethra * Patients who have had urological instrumentation to the urinary tract within 14 days prior to the test * Male patients undergoing active treatment for prostatitis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity, specificity and negative predictive value (NPV) of ADXBLADDDER will be calculated to establish the diagnostic accuracy for the detection of bladder cancer recurrence. | Urine samples will be collected from participants immediately prior to cystoscopy and analysed for MCM5 within 6 months. Overall performance characteristics of ADXBLADDER will be established following study completion. | The ADXBLADDER MCM5 results will be compared with the definitive diagnosis obtained by gold standard cystoscopy and pathological assessment of suspicious lesion(s) (where clinically indicated). |
Countries
United States
Contacts
Primary ContactJacqueline Stockley, PhD
Outcome results
None listed